Authors
»
Liu K, Zhou S, Liu J, Wang Y, Zhu F, Liu M -More
Category
»
Primary study
Journal»Drug design, development and therapy
Year
»
2019
AIM: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease.
Silibinin is a flavonoid compound which has medicinal value. Previous studies
revealed that silibinin exhibited an anti-fibrotic effect. However, whether
silibinin could attenuate high-fat diet (HFD)-induced renal fibrosis remains
unclear. Therefore, this study aimed to explore the molecular mechanism by which
silibinin regulated renal fibrosis induced by HFD. METHODS: In the present study,
human renal glomerular endothelial cells (HRGECs) were treated with various
concentrations of silibinin. Then, cell viability and apoptosis were measured by
MTT assay and flow cytometry, respectively. In addition, HRGECs were exposed to
100 nM TGF-β1 for mimicking in vitro renal fibrosis. The expressions of collagen
I, fibronectin, and α-SMA were detected by reverse transcription-quantitative
polymerase chain reaction and Western blot. Protein levels of p-IκB and p-p65
were examined by Western blot; meanwhile, level of NF-κB was measured by
immunofluorescence staining. Furthermore, HFD-induced mouse model of renal
fibrosis was established. The mouse body weight, fasting glucose, kidney
weight/body weight, microalbuminuria, kidney histopathology, and fibrotic area
were measured to assess the severity of renal fibrosis. RESULTS: Low
concentration of silibinin (≤50 μM) had no cytotoxicity, while high concentration
of silibinin (≥75 μM) exhibited significant cytotoxicity. Additionally, TGF-β1
increased the expressions of collagen I, fibronectin, α-SMA, p-IκB, and p-p65 and
decreased the level NF-κB, while these effects were notably reversed by 50 μM
silibinin. Moreover, both 50 and 100 mg/kg silibinin greatly decreased
Epistemonikos ID: 5b0e0a08611ac2b7848c4dc2f70fe5543dae2706
First added on: Jun 09, 2025